X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis

+0.06 (+4.88%)
(As of 05:13 PM ET)
Today's Range
50-Day Range
52-Week Range
1.72 million shs
Average Volume
2.18 million shs
Market Capitalization
$216.64 million
P/E Ratio
Dividend Yield
Price Target

X4 Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
132.6% Upside
$3.00 Price Target
Short Interest
7.34% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.77mentions of X4 Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$170,428 Sold Last Quarter
Proj. Earnings Growth
From ($0.47) to ($0.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.29 out of 5 stars

Medical Sector

126th out of 909 stocks

Biological Products, Except Diagnostic Industry

13th out of 156 stocks

XFOR stock logo

About X4 Pharmaceuticals Stock (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

XFOR Stock Price History

XFOR Stock News Headlines

X4 Pharmaceuticals: PDUFA Excitement Ahead
Pentagon contract could send this $2 AI stock soaring
Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on
Pentagon contract could send this $2 AI stock soaring
Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on
Q4 2023 X4 Pharmaceuticals Inc Earnings Call
XFOR Jan 2026 1.000 call
XFOR Apr 2024 1.500 call
X4 Pharmaceuticals Inc (XFOR)
XFOR Mar 2024 1.500 put
X4 Pharmaceuticals Inc.
XFOR May 2024 1.500 call
XFOR Jan 2025 1.500 call
XFOR Mar 2024 1.000 put
See More Headlines
Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.31 per share


Free Float
Market Cap
$209.98 million
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Paula Ragan Ph.D. (Age 54)
    CEO, President & Director
    Comp: $963.58k
  • Dr. Mary DiBiase Ph.D. (Age 63)
    Chief Operating Officer
    Comp: $661.59k
  • Dr. Richard Peters M.D. (Age 61)
    Ph.D., Founder
  • Dr. Renato T. Skerlj Ph.D.
  • Dr. Keith T. Flaherty M.D. (Age 53)
    Founder & Member of Corporate Advisory Board
  • Dr. Arthur Taveras Ph.D. (Age 60)
    Chief Scientific Officer
  • Dr. Glenn Schulman M.P.H.
    Pharm. D., Pharm.D., Vice President of Investor Relations & Corporate Communications
  • Dr. Robert David Arbeit (Age 76)
    Senior Vice President of Clinical Development and Translational Research
  • Mr. Mark Baldry M.B.A. (Age 60)
    Chief Commercial Officer
  • Dr. Christophe Arbet-Engels M.B.A. (Age 62)
    M.D., Ph.D., Chief Medical Officer

XFOR Stock Analysis - Frequently Asked Questions

Should I buy or sell X4 Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" XFOR shares.
View XFOR analyst ratings
or view top-rated stocks.

What is X4 Pharmaceuticals' stock price target for 2024?

2 brokers have issued 12-month price objectives for X4 Pharmaceuticals' shares. Their XFOR share price targets range from $1.00 to $5.00. On average, they anticipate the company's share price to reach $3.00 in the next year. This suggests a possible upside of 132.6% from the stock's current price.
View analysts price targets for XFOR
or view top-rated stocks among Wall Street analysts.

How have XFOR shares performed in 2024?

X4 Pharmaceuticals' stock was trading at $0.8385 at the beginning of the year. Since then, XFOR shares have increased by 53.8% and is now trading at $1.29.
View the best growth stocks for 2024 here

When is X4 Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our XFOR earnings forecast

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) issued its quarterly earnings results on Thursday, March, 21st. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.05.

What ETFs hold X4 Pharmaceuticals' stock?

ETFs with the largest weight of X4 Pharmaceuticals (NASDAQ:XFOR) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).Simplify Propel Opportunities ETF (SURI).

What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XFOR) was last updated on 4/24/2024 by Staff

From Our Partners